Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 6, 2011, Pages 564-574

  Park, Sunmin ^a   Kim, Da Sol ^a   Daily, James W ^b   Kim, Sung Hoon ^c  

^a Hoseo University   (South Korea)

^b Daily Manufacturing Inc   (United States)

^c Kwandong University College of Medicine   (South Korea)

Author keywords

cell mass; Glucose tolerance; Insulin resistance; Prolactin; Proliferation

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; METHIONINE; PROLACTIN; STAT5 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYDROCORTISONE; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; PANCREATECTOMY; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 80052567558     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1215     Document Type: Article

References (45)

1. Sachdeva MM, Stoffers DA. Minireview: meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion. Mol Endocrinol 2009; 23: 747-758.
2. Song SH, McIntyre SS, Shah H, et al. Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 2000; 85: 4491-4499.
3. Matveyenko AV, Veldhuis JD, Butler PC. Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and β-cell mass to age-related insulin resistance in rats. Am J Physiol Endocrinol Metab 2008; 295: 832-841.
4. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 2000; 11: 375-378.
5. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631.
6. Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol 2008; 20: 752-763.
7. Crabtree JS, Scacheri PC, Ward JM, et al. Of mice and MEN1, insolinomas in a conditional mouse knockout. Mol Cell Biol 2003; 23: 6075-6085.
8. Karnik SK, Chen H, McClean GW, et al. Menin controls growth of pancreatic β-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007; 318: 806-809.
9. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16: 804-808.
10. Hosokawa YA, Hosokawa H, Chen C, Leahy JL. Mechanism of impaired glucose-potentiated insulin-secretion in diabetic 90 percent pancreatectomy rats-study using glucagon-like peptide-1 (7-37). J Clin Invest 1996; 97: 180-186.
11. Park S, Hong SM, Ahn IS, Kim SH. Olanzapine, not risperidone, exacerbates β-cell function and mass in ovariectomized diabetic rats and estrogen replacement reversed them. J Psychopharmacol 2010; 24: 1105-1114.
12. Choi SB, Jang JS, Park S. Estrogen and exercise may enhance beta-cell function and mass via IRS2 induction in ovariectomized diabetic rats. Endocrinology 2005; 146: 4786-4794.
13. Committee of the American Institute of Nutrition. Ad Hoc committee on standards for nutritional studies. J Nutr 1997; 107: 1340-1348.
14. Dobbins RL, Szczepaniak LS, Myhill J, et al. The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. Diabetes 2002; 51: 1825-1833.
15. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-446.
16. Rooman I, Lardon J, Bouwen L. Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 2002; 51: 686-690.
17. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17: 110-116.
18. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Rev 1998; 19: 225-268.
19. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: and insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147: 77-84.
20. Galluzi F, Salti R, Stagi S, et al. Reversible weight gain and prolactin levels-long-term follow-up in childhood. J Pediatr Endocrinol Metab 2005; 18: 921-924.
21. Freemark M, Avril I, Fleenor D, et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 2002; 143: 1378-1385.
22. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900-903.
23. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
24. Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes 2002; 51: S394-S404.
25. Cerf ME. High fat diet modulation of glucose sensing in the beta-cell. Med Sci Monit 2007; 13: RA12-RA17.
26. Asghar Z, Yau D, Chan F, et al. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia 2006; 49: 90-99.
27. Byatt JC, Staten NR, Salsgiver WJ, et al. Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol Endocrinol Metab 1993; 264: E986-E992.
28. Kok P, Roelfsema F, Frölich M, et al. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004; 89: 4445-4449.
29. Ling C, Hellgren G, Gebre-Medhin K, et al. Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice. Endocrinology 2000; 141: 3564-3572.
30. Freemark M, Fleenor D, Driscoll P, et al. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology 2001; 142: 532-537.
31. Matsuda M, Moria T, Sassa S, et al. Chronic effect of hyperprolactinemia on blood glucose and lipid levels in mice. Life Sci 1996; 58: 1171-1177.
32. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007; 9: 464-476.
33. Ling C, Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology 2001; 142: 4880-4890.
34. Viengchareun S, Bouzinba-Segard H, Laigneau J-P, et al. Prolactin potentiates insulin-stimulated leptin expression and release from differentiated brown adipocytes. J Mol Endocrinol 2004; 33: 679-691.
35. Combs TP, Berg AH, Rajala MW, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003; 52: 268-276.
36. Nilsson L, Binart N, Bohlooly Y, et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun 2005; 331: 1120-1126.
37. Asai-Sato M, Okamoto M, Endo M, et al. Hypoadiponectinemia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006; 53: 555-562.
38. Li M, Kim DH, Tsenovoy PL, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57: 1526-1535.
39. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol 2007; 40: 55-67.
40. Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest 2003; 26: 655-659.
41. Tuzcu A, Yalaki S, Arikan S, et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary 2009; 12: 330-334.
42. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 1997; 153: 423-428.
43. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-1707.
44. Adam TC, Hasson RE, Ventura EE, et al. Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. J Clin Endocrinol Metab 2010; 95: 4729-4735.
45. Jones TH, Arver S, Behre HM, et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care 2011; 34: 828-837.